I thought it was a quite stellar result, which blew my expectations out of the water:
Because of the uncertainty surrounding the amalgam, exchange rate movements, and the Brazilian business, I had been running with two scenarios in my financial model, in relation to the second-half:
1. LOW: EBITDA = $7.2m and NPAT = $3.5m
2. HIGH: EBITDA = $7.7m and NPAT = $3.8m
These compare with the reported result:
ACTUAL: EBITDA = $8.4m and NPAT = $4.5m.
So the result left even my bullish expectation for dead.
(Which just goes to show, once again, how inept a financial modeller and forecaster I am.)
There were several notable positives specifically in the second-half result:
- After EBIT for the first half (the seasonally weaker half) was down 45% on pcp, for second-half EBIT was 22% higher than pcp; as a result, full-year result was flat on pcp.
- the Gross Profit Margin of 62.6% which is at a decade-high (pcp GP Margin was 59.9% and H1 GP Margin was 59.3%)
- a $1.2m reduction in working capital vs 30 June 2017, despite higher Revenue
- Net cash balance of $6m (c.f., $1.6m @ 30 June 2017)
- Acceleration in sales growth of SDI's largest product categories: In local currency terms, Aesthetics sales (39% of Group Total Sales) grew by 9.8% vs pcp in the second-half (c.f., 8.7% in first-half) and Whitening product sales (26%of Total Sales increased by 1.8% in second-half (c.f., zero growth in the first half)
Of course, there were not only bouquets in the result.
A few brickbats were present, too:
- US Revenues continue to go backwards. This is a concern because it is a big market for SDI (~24% of current Group Total Sales)
- Brazil is still not performing, and now there is some reference to setting up some sort of a manufacturing facility in Brazil
- While at a modestly slower rate, sales of Amalgam products continues to fall (down 11.4%in second-half on pcp, compared to 14.3% fall in the first-half). Amalgam now represents 26% of Total Group Sales, down from 45% five years ago. So its drag influence on the top line is diminishing each year.
- Equipment Sales (9% of Total Sales) were down 3% in the second-half, compared to 1.9% reduction in the first-half
Wrapping all this up, I reckon SDI will generate EBITDA of around $14m this year, and EBIT of around $10m to $11m.
The net cash position this time next year will be around $8m
Which means that, at yesterday's closing price, the stock is trading on 3.5x EV/EBITDA and less than 5x EV/EBIT.
- Forums
- ASX - By Stock
- Ann: Preliminary Final Report
SDI
sdi limited
Add to My Watchlist
2.55%
!
86.0¢

I thought it was a quite stellar result, which blew my...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
86.0¢ |
Change
-0.023(2.55%) |
Mkt cap ! $102.2M |
Open | High | Low | Value | Volume |
88.0¢ | 88.0¢ | 86.0¢ | $24.50K | 28.46K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 215 | 86.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
87.0¢ | 22540 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 215 | 0.860 |
3 | 33231 | 0.845 |
2 | 11190 | 0.840 |
2 | 31200 | 0.830 |
3 | 10758 | 0.820 |
Price($) | Vol. | No. |
---|---|---|
0.870 | 22540 | 2 |
0.880 | 4328 | 1 |
0.885 | 1879 | 2 |
0.890 | 7395 | 2 |
0.900 | 75000 | 1 |
Last trade - 13.31pm 01/08/2025 (20 minute delay) ? |
Featured News
SDI (ASX) Chart |
The Watchlist
AFP
AFT PHARMACEUTICALS LIMITED
Hartley Atkinson, CEO & Founder
Hartley Atkinson
CEO & Founder
Previous Video
Next Video
SPONSORED BY The Market Online